Recurrent human papillomavirus-related head and neck cancer undergoes metabolic re-programming and is driven by oxidative phosphorylation
A. VYAS, R. A. Harbison, D. Faden, M. Kubik, D. Palmer, Q. Zhang, H. Osmanbeyoglu, E. Mendez, U. Duvvuri
This study identifies oxidative phosphorylation as a driver of treatment failure in recurrent HPV-related head and neck cancer, highlighting Nrf2 as a therapeutic target.
bioRxiv · Aug 21, 2020Cancer Biology